Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Tsutomu Yanagisawa"'
Autor:
Taisuke Isono, Naho Kagiyama, Shun Shibata, Hitomi Nakajima, Yuma Matsui, Kenji Takano, Takashi Nishida, Chiaki Hosoda, Eriko Kawate, Yoichi Kobayashi, Takashi Ishiguro, Yotaro Takaku, Kazuyoshi Kurashima, Tsutomu Yanagisawa, Noboru Takayanagi
Publikováno v:
Thoracic Cancer, Vol 12, Iss 9, Pp 1387-1397 (2021)
Abstract Background Although clinical trials have investigated the addition of pembrolizumab to chemotherapy for non‐small cell lung cancer, none have investigated the addition of chemotherapy to pembrolizumab. Methods We conducted a retrospective
Externí odkaz:
https://doaj.org/article/5ef23fc521cd4c0baccdca9b0b6b437b
Publikováno v:
JA Clinical Reports, Vol 6, Iss 1, Pp 1-3 (2020)
Externí odkaz:
https://doaj.org/article/382eb85f079847deb60f6b383cbe7864
Autor:
Takashi Ishiguro, Kenji Takano, Naho Kagiyama, Chiaki Hosoda, Yoichi Kobayashi, Yotaro Takaku, Naomi Takata, Miyuki Ueda, Yasuhiro Morimoto, Keisuke Kasuga, Ryota Ozawa, Taisuke Isono, Takashi Nishida, Eriko Kawate, Yasuhito Kobayashi, Yoshihiko Shimizu, Kazuyoshi Kurashima, Tsutomu Yanagisawa, Noboru Takayanagi
Publikováno v:
Respiratory Medicine Case Reports, Vol 31, Iss , Pp 101207- (2020)
Objective: To clarify what future problems must be resolved and how clinical findings of SARS-CoV-2 infection differ from those of cHCoV infection. Methods: Patients and Methods Clinical characteristics of 14 patients with laboratory-confirmed Corona
Externí odkaz:
https://doaj.org/article/0223f87e617a4ad08b1642dd7d72ffb5
Autor:
Yuki Yoshida, Yotaro Takaku, Yasuo Nakamoto, Noboru Takayanagi, Tsutomu Yanagisawa, Hajime Takizawa, Kazuyoshi Kurashima
Publikováno v:
PLoS ONE, Vol 15, Iss 2, p e0229238 (2020)
BACKGROUND:Airway obstruction due to decreased airway diameter and increased incidence of mucus plugs has not been directly observed in asthma exacerbation. We studied the changes in the inner diameter of the airway (Din) and the frequency of mucus p
Externí odkaz:
https://doaj.org/article/c1b947ef79344e43a291c84d07b0d90f
Autor:
Yusuke Sakurai, Yoshiyuki Takami, Akihiro Kobayashi, Tsutomu Yanagisawa, Kentaro Amano, Yoshiro Higuchi, Masato Tochii, Michiko Ishida, Toshimitsu Satou, Hiroshi Ishikawa, Masayoshi Kobayashi, Koji Hattori, Motomi Ando, Yasushi Takagi
Publikováno v:
Fujita Medical Journal, Vol 3, Iss 3, Pp 62-66 (2017)
Objectives: Pulmonary endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH) is technically demanding. We reviewed the surgical outcomes of consecutive patients who underwent PEA with aggressive use of pulmonary vasodilators,
Externí odkaz:
https://doaj.org/article/d9bb5b488d53489fa50283275b200552
Autor:
Taisuke Isono, Jiro Hasemi, Airi Hasegawa, Takashi Nishida, Chiaki Hosoda, Eriko Kawate, Yoichi Kobayashi, Takashi Ishiguro, Naho Kagiyama, Kazuyoshi Kurashima, Tsutomu Yanagisawa, Noboru Takayanagi
Purpose No clinical trial has compared osimertinib with afatinib. We reviewed clinical data of patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) to identify predictive factors for clinical outcome of fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::502e06f82c943528b7abf7dc0e56443e
https://doi.org/10.21203/rs.3.rs-2128762/v1
https://doi.org/10.21203/rs.3.rs-2128762/v1
Autor:
Tsutomu Yanagisawa, Naho Kagiyama, Kazuyoshi Kurashima, Kenji Takano, Takashi Nishida, Eriko Kawate, Taisuke Isono, Yoichi Kobayashi, Youtaro Takaku, Noboru Takayanagi, Chiaki Hosoda, Takashi Ishiguro
Publikováno v:
Thoracic Cancer
Background Non‐small cell lung cancer (NSCLC) patients with pre‐existing respiratory diseases have been excluded in clinical trials of immune checkpoint inhibitor (ICI) therapy, and it is unknown whether the same degree of response can be expecte
Autor:
Kazuyoshi Kurashima, Tsuyoshi Numano, Atsuki Yoshino, Akiko Osawa, Yotaro Takaku, Naho Kagiyama, Tsutomu Yanagisawa
Publikováno v:
Vaccine. 40(39)
Antibody levels decrease substantially at 6 months after the BNT162b2 vaccine. The factors influencing titer of antibodies against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) among healthcare workers for coronavirus disease 2019 (COV
Autor:
Yotaro Takaku, Tsuyoshi Numano, Taisuke Isono, Mayumi Koike, Takashi Ishiguro, Yoichi Kobayashi, Kenji Takano, Eriko Kawate, Naho Kagiyama, Takashi Nishida, Tsutomu Yanagisawa, Chiaki Hosoda, Kazuyoshi Kurashima, Susumu Yokota
Publikováno v:
Kansenshogaku Zasshi
An immunochromatographic assay that has been developed for the detection of antibodies in blood-derived specimens is raising expectations for the diagnosis of COVID-19, the disease caused by the novel corona virus SARS-CoV-2 Herein, we studied the in
Autor:
Takashi Ishiguro, Kazuyoshi Kurashima, Noboru Takayanagi, Chiaki Hosoda, Yasuhiro Morimoto, Youichi Kobayashi, Keisuke Kasuga, Eriko Kawate, Naho Kagiyama, Takashi Nishida, Kenji Takano, Yotaro Takaku, Tsutomu Yanagisawa, Ryouta Ozawa, Taisuke Isono
Publikováno v:
Kansenshogaku Zasshi
In patients with COVID-19, age over 50 years is also considered as an indication for antiviral drug therapy, in addition to hypoxemia At this time, it still remains unclear as to which clinical markers can be considered as being predictive of severe